TMEM267

Across TCGA pan-cancer cohorts, TMEM267 RNA is linked to patient survival in 21 of 34 cancer types, making it the most broadly survival-associated TMEM267 data layer compared with 4 for mutation status and 1 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher TMEM267 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM267 expression acts as an unfavorable survival marker, although some lineages such as ACC and BLCA show a favorable association.

LIHC, UVM, and CESC are the cancer types where TMEM267 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.708	0.842	<.001	87	view →
UVM	DFS	Quartile	All	0.321	0.896	<.001	73	view →
CESC	DFS	Median	III,IV	0.196	0.721	<.001	58	view →
LGG	OS	Median	All	0.749	0.867	<.001	46	view →
MESO	OS	Tertile	All	0.252	0.542	<.001	45	view →
SCLC	OS	Quartile	All	0.239	0.659	<.001	35	view →
KICH	DFS	Quartile	III,IV	0.223	1.000	.004	33	view →
UCEC	OS	Quartile	II,III,IV	0.659	0.826	.024	20	view →
ACC	OS	Median	IV	0.799	0.287	.006	16	view →
BLCA	DFS	Quartile	III,IV	0.611	0.405	.003	11	view →
KIRC	DFS	Median	III,IV	0.662	0.829	.010	11	view →
DLBC	DFS	Median	All	0.629	1.000	.017	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 21 lineages.

TMEM267–LIHC (OS)

Open the LIHC breakdown →